# Elranatamab in Relapsed/Refractory Multiple Myeloma

> **NCT06711705** · PHASE2 · RECRUITING · sponsor: **University of California, San Diego** · enrollment: 33 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Elranatamab

## Key facts

- **NCT ID:** NCT06711705
- **Lead sponsor:** University of California, San Diego
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-18
- **Primary completion:** 2029-12
- **Final completion:** 2030-12
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06711705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06711705, "Elranatamab in Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06711705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*